Gary Zammit

Summary

Affiliation: Columbia University College of Physicians and Surgeons
Country: USA

Publications

  1. ncbi request reprint Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
    Gary K Zammit
    Columbia University College of Physicians and Surgeons, New York 10025, USA
    Curr Med Res Opin 20:1979-91. 2004
  2. doi request reprint The effects of ramelteon in a first-night model of transient insomnia
    Gary Zammit
    Clinilabs Sleep Disorder Institute, 423 West 55th Street, New York, NY 10019, USA
    Sleep Med 10:55-9. 2009
  3. ncbi request reprint Zolpidem extended-release: therapy for sleep induction and sleep maintenance difficulties
    Gary Zammit
    Clinilabs, Inc, 423 W 55th Street 4th Floor, New York, NY 10019, USA
    Expert Opin Drug Metab Toxicol 4:325-31. 2008
  4. pmc Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia
    Gary Zammit
    Clinilabs, Inc, 423 West 55th Street, 4th Floor, New York, NY 10019, USA
    J Clin Sleep Med 5:34-40. 2009
  5. doi request reprint Comparative tolerability of newer agents for insomnia
    Gary Zammit
    Clinilabs, Inc, New York, New York, USA
    Drug Saf 32:735-48. 2009
  6. pmc Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia
    Gary Zammit
    Clinilabs Sleep Disorders Institute, New York, NY 10025, USA
    J Clin Sleep Med 3:495-504. 2007
  7. ncbi request reprint Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening
    Gary K Zammit
    Clinilabs Sleep Disorders Institute, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10019, USA
    J Clin Sleep Med 2:417-23. 2006
  8. ncbi request reprint The prevalence, morbidities, and treatments of insomnia
    Gary K Zammit
    Clinilabs Inc, 423 West 55th Street, New York, NY 10025, USA
    CNS Neurol Disord Drug Targets 6:3-16. 2007
  9. doi request reprint Impact of nighttime awakenings on worker productivity and performance
    Gary K Zammit
    Clinilabs Inc, New York, NY 10025, USA
    J Occup Environ Med 52:513-8. 2010
  10. pmc Use of computerized dynamic posturography to assess balance in older adults after nighttime awakenings using zolpidem as a reference
    Gary Zammit
    Clinilabs and the Columbia University College of Physicians and Surgeons, New York, NY, USA
    BMC Geriatr 8:15. 2008

Detail Information

Publications22

  1. ncbi request reprint Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
    Gary K Zammit
    Columbia University College of Physicians and Surgeons, New York 10025, USA
    Curr Med Res Opin 20:1979-91. 2004
    ..The present study was a randomized, double-blind, multicenter, placebo-controlled trial conducted to assess the efficacy and safety of eszopiclone in adults with chronic primary insomnia...
  2. doi request reprint The effects of ramelteon in a first-night model of transient insomnia
    Gary Zammit
    Clinilabs Sleep Disorder Institute, 423 West 55th Street, New York, NY 10019, USA
    Sleep Med 10:55-9. 2009
    ..To evaluate the efficacy and safety of ramelteon, a highly selective MT(1)/MT(2) melatonin receptor agonist, for the treatment of transient insomnia in adults...
  3. ncbi request reprint Zolpidem extended-release: therapy for sleep induction and sleep maintenance difficulties
    Gary Zammit
    Clinilabs, Inc, 423 W 55th Street 4th Floor, New York, NY 10019, USA
    Expert Opin Drug Metab Toxicol 4:325-31. 2008
    ..Although primary and co-morbid insomnias are presented to clinicians in healthcare settings, physicians may need to apply direct inquiry in order to elicit patient reports of insomnia...
  4. pmc Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia
    Gary Zammit
    Clinilabs, Inc, 423 West 55th Street, 4th Floor, New York, NY 10019, USA
    J Clin Sleep Med 5:34-40. 2009
    ..To evaluate the effect of ramelteon on middle-of-the-night balance, mobility, and memory in older insomniacs...
  5. doi request reprint Comparative tolerability of newer agents for insomnia
    Gary Zammit
    Clinilabs, Inc, New York, New York, USA
    Drug Saf 32:735-48. 2009
    ....
  6. pmc Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia
    Gary Zammit
    Clinilabs Sleep Disorders Institute, New York, NY 10025, USA
    J Clin Sleep Med 3:495-504. 2007
    ..To evaluate efficacy and safety of ramelteon (MT1/MT2-receptor [corrected] agonist) in subjects with chronic primary insomnia...
  7. ncbi request reprint Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening
    Gary K Zammit
    Clinilabs Sleep Disorders Institute, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, NY 10019, USA
    J Clin Sleep Med 2:417-23. 2006
    ....
  8. ncbi request reprint The prevalence, morbidities, and treatments of insomnia
    Gary K Zammit
    Clinilabs Inc, 423 West 55th Street, New York, NY 10025, USA
    CNS Neurol Disord Drug Targets 6:3-16. 2007
    ..This article presents existing approaches to insomnia treatment, and reviews new treatments, therapeutic targets, and treatment approaches to insomnia under development that may offer promise to practitioners and patients...
  9. doi request reprint Impact of nighttime awakenings on worker productivity and performance
    Gary K Zammit
    Clinilabs Inc, New York, NY 10025, USA
    J Occup Environ Med 52:513-8. 2010
    ..To describe the relationship between nighttime awakenings and work performance...
  10. pmc Use of computerized dynamic posturography to assess balance in older adults after nighttime awakenings using zolpidem as a reference
    Gary Zammit
    Clinilabs and the Columbia University College of Physicians and Surgeons, New York, NY, USA
    BMC Geriatr 8:15. 2008
    ..The goal of the current pilot study was to evaluate balance in healthy older adults after a middle-of-the-night awakening and to assess the ability of CDP to measure effects of bedtime zolpidem administration...
  11. pmc A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia
    Milton K Erman
    Pacific Sleep Medicine Services, Inc, San Diego, CA, USA
    J Clin Sleep Med 4:229-34. 2008
    ..To evaluate the polysomnographic efficacy and the safety of a range of doses of eszopiclone relative to placebo in patients with primary insomnia. Zolpidem 10 mg was included as an active control...
  12. doi request reprint Insomnia and sleep duration as mediators of the relationship between depression and hypertension incidence
    James E Gangwisch
    Division of Cognitive Neuroscience, Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Am J Hypertens 23:62-9. 2010
    ..No previous published population studies have examined whether insomnia and sleep duration mediate the relationship between depression and hypertension incidence...
  13. pmc Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample
    James E Gangwisch
    Columbia University, College of Physicians and Surgeons, Department of Psychiatry, Division of Medical Genetics, New York, NY 10032, USA
    Sleep 31:1087-96. 2008
    ..No epidemiologic studies have published multivariate analyses stratified by age, even though life expectancy is 75 years and the majority of deaths occur in the elderly...
  14. pmc Earlier parental set bedtimes as a protective factor against depression and suicidal ideation
    James E Gangwisch
    Columbia University, College of Physicians and Surgeons, Department of Psychiatry, New York, NY 10032, USA
    Sleep 33:97-106. 2010
    ..Depression in an adolescent can affect his/her chosen bedtime, but it is less likely to affect a parent's chosen set bedtime which can establish a relatively stable upper limit that can directly affect sleep duration...
  15. pmc Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health
    James E Gangwisch
    Columbia University, College of Physicians and Surgeons, Department of Psychiatry, Division of Cognitive Neuroscience, 1051 Riverside Drive, Unit 74, New York, NY 10032, USA
    Sleep 33:956-61. 2010
    ..No previous published population studies have examined the longitudinal relationship between sleep duration and high cholesterol...
  16. pmc Sleep duration as a risk factor for diabetes incidence in a large U.S. sample
    James E Gangwisch
    Columbia University, College of Physicians and Surgeons, Department of Psychiatry, Division of Medical Genetics, 1051 Riverside Drive, Mailbox 2, New York, NY 10032, USA
    Sleep 30:1667-73. 2007
    ..No plausible mechanism has been identified by which long sleep duration could lead to diabetes...
  17. ncbi request reprint Short sleep duration as a risk factor for hypertension: analyses of the first National Health and Nutrition Examination Survey
    James E Gangwisch
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA
    Hypertension 47:833-9. 2006
    ..Short sleep duration could, therefore, be a significant risk factor for hypertension...
  18. pmc Efficacy and safety of as-needed, post bedtime dosing with indiplon in insomnia patients with chronic difficulty maintaining sleep
    Thomas Roth
    Sleep Disorders and Research Center, Department of Psychiatry and Behavioral Neurosciences Henry Ford Hospital, 2799 West Grand Blvd, CEP 3, Detroit, MI 48202, USA
    Sleep 30:1731-8. 2007
    ....
  19. pmc Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study
    Andrew D Krystal
    Duke University Medical Center, Durham, NC 27710, USA
    Sleep 31:79-90. 2008
    ..To evaluate long-term efficacy and safety of zolpidem extended-release 3 to 7 nights/week for chronic primary insomnia...
  20. ncbi request reprint Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo
    David J Greenblatt
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA
    J Clin Pharmacol 46:1469-80. 2006
    ..001). Thus, MR zolpidem produces sustained plasma levels compared to IR, with resulting enhancement of pharmacodynamic effects in the 3- to 6-hour post-dosage interval...
  21. ncbi request reprint A polysomnography study of eszopiclone in elderly patients with insomnia
    W Vaughn McCall
    Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Curr Med Res Opin 22:1633-42. 2006
    ..To evaluate the safety and efficacy of eszopiclone 2 mg in elderly patients (aged 64-86 years) with chronic insomnia...
  22. pmc Insufficient evidence for the use of automated and semi-automated scoring of polysomnographic recordings
    Gary K Zammit
    Sleep 31:449-50; author reply 451. 2008